| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
mGluR1a 8.8 μM (IC50)
|
|---|---|
| ln Vitro |
Maximum reductions in NMDA toxicity range from 40% to 60%. LY367385 hydrochloride binds to N-methyl-D-aspartate (NMDA) during hazardous pulses, attenuating neuronal degeneration in a concentration-dependent way. LY367385 hydrochloride was more effective than LY367366, and none of these substances by itself had any effect on the vitality of neurons. At a dose of 10 nM, LY367385 hydrochloride demonstrated strong neuroprotection and a 50% reduction in the potentiating impact of (S)-3,5-dihydroxyphenylglycine (DHPG). Under experimental conditions involving greater antagonist doses, the amplifying impact of DHPG on NMDA toxicity was fully neutralized by LY367385 hydrochloride [2].
|
| ln Vivo |
Intracerebroventricular (icv) administration of LY367385 hydrochloride has been used in DBA/2 mice and somnolescent mice (lh/lh), as well as central administration to the inferior colliculus of rats that are genetically prone to epilepsy (GEPR). LY367385 hydrochloride (ED50=12 nM, icv, 5 minutes) quickly and transiently inhibited sound-induced clonic seizures in DBA/2 mice. Following the treatment of LY367385 hydrochloride (250 nM) icv, the occurrence of spontaneous spikes and wave discharges on the electroencephalogram was dramatically reduced in sleepy mice [3]. This reduction occurred from 30 minutes to >150 minutes. Rats prone to hereditary epilepsy experience less clonic seizures when exposed to LY367385 hydrochloride. After two to four hours, LY367385 hydrochloride at 160 nM on both sides totally prevents clonic seizures [3].
|
| References |
[1]. Clark et al. (+)-2-Methyl-4-carboxyphenylglycine (LY 367385) selectively antagonises metabotropic glutamate mGluR1 receptors. Bioorg.Med.Chem.Lett. November 1997, 7 (21): 2777-2780.
[2]. Bruno V, et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999 Feb;38(2):199-207. [3]. Chapman AG, et al. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24. |
| Molecular Formula |
C10H12CLNO4
|
|---|---|
| Molecular Weight |
245.66
|
| CAS # |
2829282-00-8
|
| Related CAS # |
LY367385;198419-91-9
|
| SMILES |
OC(C1C=CC([C@@H](C(=O)O)N)=C(C)C=1)=O.Cl
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (508.83 mM)
H2O: 12.5 mg/mL (50.88 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (203.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0707 mL | 20.3533 mL | 40.7067 mL | |
| 5 mM | 0.8141 mL | 4.0707 mL | 8.1413 mL | |
| 10 mM | 0.4071 mL | 2.0353 mL | 4.0707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
